Back to top
more

ABIOMED, Inc. (ABMD)

(Delayed Data from NSDQ)

$324.55 USD

324.55
430,002

+4.08 (1.27%)

Updated Feb 26, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (171 out of 253)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for ABMD More Info

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for ABIOMED, Inc. falls in the month of March.

All items in Millions except Per Share data.

3/31/2020 3/31/2019 3/31/2018 3/31/2017 3/31/2016
Assets          
Cash & Equivalents 443 492 362 230 212
Receivables 85 91 70 54 43
Notes Receivable 0 0 0 0 0
Inventories 90 81 50 35 27
Other Current Assets 18 14 12 8 7
Total Current Assets 636 677 494 327 288
Net Property & Equipment 165 145 117 88 23
Investments & Advances 208 22 38 47 1
Other Non-Current Assets 15 15 17 14 15
Deferred Charges 43 78 71 35 59
Intangibles 32 33 36 31 33
Deposits & Other Assets 118 85 14 8 4
Total Assets 1,216 1,054 786 550 424
Liabilities & Shareholders Equity 3/31/2020 3/31/2019 3/31/2018 3/31/2017 3/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 33 32 24 21 9
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 1 0
Accrued Expenses 75 57 46 38 28
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 24 16 15 11 9
Total Current Liabilities 132 106 85 70 47
Mortgages 0 0 0 0 0
Deferred Taxes/Income 1 1 1 1 1
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 16 0
Other Non-Current Liabilities 18 11 11 12 8
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 151 117 97 98 55
Shareholders Equity 3/31/2020 3/31/2019 3/31/2018 3/31/2017 3/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 739 691 620 566 509
Retained Earnings 602 399 140 -47 -99
Other Equity -11 -15 -4 -21 -15
Treasury Stock 265 139 67 47 27
Total Shareholder's Equity 1,065 937 690 452 369
Total Liabilities & Shareholder's Equity 1,216 1,054 786 550 424
Total Common Equity 1,065 937 690 452 369
Shares Outstanding 45.00 45.00 44.20 43.50 42.40
Book Value Per Share 23.68 20.82 15.60 10.39 8.70

Fiscal Year End for ABIOMED, Inc. falls in the month of March.

All items in Millions except Per Share data.

12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Assets          
Cash & Equivalents 486 533 427 443 428
Receivables 93 81 82 85 101
Notes Receivable 0 0 0 0 0
Inventories 82 83 89 90 91
Other Current Assets 32 19 21 18 17
Total Current Assets 694 717 620 636 637
Net Property & Equipment 179 176 170 165 162
Investments & Advances 301 203 170 208 168
Other Non-Current Assets 0 43 42 15 15
Deferred Charges 21 30 31 43 47
Intangibles 123 78 77 32 33
Deposits & Other Assets 110 83 140 118 135
Total Assets 1,428 1,328 1,250 1,216 1,197
Liabilities & Shareholders Equity 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 24 22 28 33 32
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 72 57 58 75 72
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 25 26 24 24 23
Total Current Liabilities 120 105 110 132 126
Mortgages 0 0 0 0 0
Deferred Taxes/Income 4 4 4 1 1
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 42 33 18 23
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 167 146 148 151 150
Shareholders Equity 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 782 768 749 739 733
Retained Earnings 771 709 647 602 571
Other Equity -4 -7 -9 -11 -17
Treasury Stock 288 288 287 265 240
Total Shareholder's Equity 1,261 1,182 1,102 1,065 1,047
Total Liabilities & Shareholder's Equity 1,428 1,328 1,250 1,216 1,197
Total Common Equity 1,261 1,182 1,102 1,065 1,047
Shares Outstanding 45.20 45.10 45.00 45.00 45.00
Book Value Per Share 27.91 26.22 24.49 23.68 23.26